GlassScriptPhysician profile
Mohammed Shan Uddin
NPI 1558823211
$3,976.74
in general payments reported to CMS, 2019-2025
32 companies · $729 in 2025
The $729 reported for 2025 was more than what 76% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.23 · 2022: $726 · 2023: $1,164 · 2024: $1,325 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,133 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.04 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $550.87 | 2022-2025 | |
| Ucb, INC. | $499.62 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Amneal Pharmaceuticals LLC | $329.20 | 2022-2025 | Crexont |
| Amgen INC. | $272.94 | 2024 | Tepezza, Uplizna |
| Supernus Pharmaceuticals, INC. | $250.70 | 2023-2024 | Qelbree |
| Abbvie INC. | $231.50 | 2022-2023 | Botox |
| Merz Pharmaceuticals, LLC | $189.42 | 2023-2024 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $166.14 | 2023-2024 | Rexulti |
| Argenx US, INC. | $150.20 | 2023-2025 | Vyvgart |
| Alexion Pharmaceuticals, INC. | $132.41 | 2022-2024 | Ultomiris, Soliris |
| Catalyst Pharmaceuticals, INC. | $120.06 | 2024-2025 | |
| Neurelis, INC. | $119.87 | 2022-2024 | Valtoco |
| Idorsia Pharmaceuticals US INC | $116.50 | 2022 | |
| Jazz Pharmaceuticals INC. | $112.56 | 2022 | |
| Eisai INC. | $84.58 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $72.95 | 2023 | |
| Biogen, INC. | $72.20 | 2022-2025 | Spinraza, Tysabri, Vumerity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.42 | 2024 | Rexulti |
| Saluda Medical Americas, INC. | $52.25 | 2025 | Evoke |
| Lilly USA, LLC | $49.78 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $41.34 | 2023-2024 | Austedo, Austedo Xr |
| Revance Therapeutics, INC. | $39.61 | 2024 | Daxxify |
| Octapharma USA, INC. | $39.40 | 2023-2024 | Panzyga |
| Sk Life Science, INC. | $34.95 | 2022 | |
| Acorda Therapeutics, INC | $34.30 | 2022-2023 | Inbrija |
| Mdd US Operations, LLC | $32.37 | 2023 | Apokyn |
| Neurocrine Biosciences, INC. | $26.92 | 2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $25.85 | 2023 | Jornay Pm |
| Ani Pharmaceuticals, INC. | $21.93 | 2024 | Purified Cortrophin Gel |
| Pfizer INC. | $21.67 | 2023 | |
| Allergan, INC. | $18.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.